|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Biovail Corporation (BVF), a Canada-based specialty pharmaceutical company. |
|---|---|
| Transferring Party | Santhera, a Swiss-based biotech company. |
| Sector | Biopharmaceuticals |
| Date | August 24, 2009 |
| Analysis In its 3rd significant purchase for central nervous system treatments, Biovail gets a drug to treat dyskinesia in Parkinson's disease. The ailment causes sudden uncontrollable movements of limbs, face, tongue and body. Some 400,000 patients in Europe and North America are affected, with an estimated market of $200-$400m. Upfront payment of $8m but $184m for progress of the drug to market. The deal was in part precipitated by Santhera's lead drug Catena missing its main aim in a late-stage trial to treat a hereditary disease that damages the nervous system. Its stock has lost nearly 30% percent of its value since January 09. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2010 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |